ProMIS Neurosciences EV/EBITDA
Qual é o EV/EBITDA de ProMIS Neurosciences?
O EV/EBITDA de ProMIS Neurosciences, Inc. é N/A
Qual é a definição de EV/EBITDA?
EV/EBITDA é o valor da empresa dividido pelo lucro antes de juros, impostos, depreciação e amortização. É uma medida de quão cara é uma ação e é mais frequentemente válida para comparações entre empresas do que da relação entre preço e lucro. Ele mede o preço (na forma de valor da empresa) que um investidor paga em benefício do fluxo de caixa da empresa (na forma de EBITDA).
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV/EBITDA de empresas na Setor Health Care em OTC em comparação com ProMIS Neurosciences
O que ProMIS Neurosciences faz?
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Empresas com ev/ebitda semelhantes a ProMIS Neurosciences
- Good2 Go4 Corp tem EV/EBITDA de N/A
- 3D Resources tem EV/EBITDA de N/A
- Litian Pictures tem EV/EBITDA de N/A
- Dimerix tem EV/EBITDA de N/A
- Inogen Inc tem EV/EBITDA de N/A
- Taung Gold International tem EV/EBITDA de N/A
- ProMIS Neurosciences tem EV/EBITDA de N/A
- China Youzan tem EV/EBITDA de N/A
- PanAsialum tem EV/EBITDA de N/A
- Damstra Ltd tem EV/EBITDA de N/A
- IDT International tem EV/EBITDA de N/A
- Kalytera Therapeutics tem EV/EBITDA de N/A
- Purepoint Uranium tem EV/EBITDA de N/A